{
    "symbol": "EVAX",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-10 12:17:17",
    "content": " Starting with our oncology program, in May 2022, we announced the successful production using our PIONEER AI platform of all batches of personalized cancer immunotherapies for all patients enrolled in our Phase 1/2a clinical trial of our EVX-02 product candidate for resectable melanoma. General and administrative expenses were $2.1 million for the three months ending, June 30, 2022, as compared to $1.9 million for the same period in 2021. Net loss was $4.8 million for the three months ended, June 30, 2022 or $0.2 loss per basic and diluted shares compared to $6.8 million or $0.36 loss per basic and diluted shares for the three months ended, June 30, 2021."
}